Participants in a meeting organized by FDA, the International Life Sciences Institute's Health and Environmental Sciences Institute (HESI) and the Cardiac Safety Research Consortium (CSRC) have proposed a way to significantly improve the identification of compounds that cause pro-arrhythmia side effects such as Torsades de Pointes (TdP), a